
Fozia M. Hamud
Examiner (ID: 4706)
| Most Active Art Unit | 1647 |
| Art Unit(s) | 1646, 1647 |
| Total Applications | 1310 |
| Issued Applications | 752 |
| Pending Applications | 93 |
| Abandoned Applications | 464 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 13837425
[patent_doc_number] => 20190022197
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-24
[patent_title] => MODULATION OF YEAST-BASED IMMUNOTHERAPY PRODUCTS AND RESPONSES
[patent_app_type] => utility
[patent_app_number] => 16/143710
[patent_app_country] => US
[patent_app_date] => 2018-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44984
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16143710
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/143710 | MODULATION OF YEAST-BASED IMMUNOTHERAPY PRODUCTS AND RESPONSES | Sep 26, 2018 | Abandoned |
Array
(
[id] => 18637370
[patent_doc_number] => 11761963
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-19
[patent_title] => Biomarker signature for predicting tumor response to anti-CD200 therapy
[patent_app_type] => utility
[patent_app_number] => 16/648503
[patent_app_country] => US
[patent_app_date] => 2018-09-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 28
[patent_no_of_words] => 22118
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 145
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16648503
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/648503 | Biomarker signature for predicting tumor response to anti-CD200 therapy | Sep 25, 2018 | Issued |
Array
(
[id] => 16533333
[patent_doc_number] => 10875917
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-12-29
[patent_title] => Antagonists of IL-6 to prevent or treat thrombosis
[patent_app_type] => utility
[patent_app_number] => 16/131216
[patent_app_country] => US
[patent_app_date] => 2018-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 55
[patent_figures_cnt] => 56
[patent_no_of_words] => 102580
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16131216
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/131216 | Antagonists of IL-6 to prevent or treat thrombosis | Sep 13, 2018 | Issued |
Array
(
[id] => 13929081
[patent_doc_number] => 20190048056
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-02-14
[patent_title] => HETERODIMERS OF IL-15 AND IL-15R ALPHA TO INCREASE THYMIC OUTPUT AND TO TREAT LYMPHOPENIA
[patent_app_type] => utility
[patent_app_number] => 16/123431
[patent_app_country] => US
[patent_app_date] => 2018-09-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15029
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16123431
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/123431 | Heterodimers of IL-15 and IL-15R alpha to increase thymic output and to treat lymphopenia | Sep 5, 2018 | Issued |
Array
(
[id] => 14102353
[patent_doc_number] => 20190092852
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-03-28
[patent_title] => ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/119667
[patent_app_country] => US
[patent_app_date] => 2018-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 90756
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -61
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16119667
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/119667 | Anti-interleukin-33 antibodies and uses thereof | Aug 30, 2018 | Issued |
Array
(
[id] => 17975550
[patent_doc_number] => 11492398
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-08
[patent_title] => IL-33 antagonist-containing therapeutic agent for endometriosis
[patent_app_type] => utility
[patent_app_number] => 16/643502
[patent_app_country] => US
[patent_app_date] => 2018-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 6
[patent_no_of_words] => 10789
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16643502
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/643502 | IL-33 antagonist-containing therapeutic agent for endometriosis | Aug 30, 2018 | Issued |
Array
(
[id] => 13618813
[patent_doc_number] => 20180360958
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-20
[patent_title] => VACCINES WITH INTERLEUKIN-33 AS AN ADJUVANT
[patent_app_type] => utility
[patent_app_number] => 16/117320
[patent_app_country] => US
[patent_app_date] => 2018-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29562
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16117320
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/117320 | Vaccines with interleukin-33 as an adjuvant | Aug 29, 2018 | Issued |
Array
(
[id] => 18013327
[patent_doc_number] => 11505609
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-22
[patent_title] => Recombinant antibody having unique glycan profile produced by CHO host cell with edited genome and preparation method thereof
[patent_app_type] => utility
[patent_app_number] => 16/337371
[patent_app_country] => US
[patent_app_date] => 2018-08-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 13
[patent_no_of_words] => 10842
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16337371
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/337371 | Recombinant antibody having unique glycan profile produced by CHO host cell with edited genome and preparation method thereof | Aug 9, 2018 | Issued |
Array
(
[id] => 13576951
[patent_doc_number] => 20180340024
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-29
[patent_title] => ANTIBODIES FOR IL-17C
[patent_app_type] => utility
[patent_app_number] => 16/058143
[patent_app_country] => US
[patent_app_date] => 2018-08-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19793
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 177
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16058143
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/058143 | Antibodies for IL-17C | Aug 7, 2018 | Issued |
Array
(
[id] => 16941088
[patent_doc_number] => 11053309
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-07-06
[patent_title] => Methods for treating active eosinophilic esophagitis
[patent_app_type] => utility
[patent_app_number] => 16/054583
[patent_app_country] => US
[patent_app_date] => 2018-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 22
[patent_no_of_words] => 21665
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 152
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16054583
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/054583 | Methods for treating active eosinophilic esophagitis | Aug 2, 2018 | Issued |
Array
(
[id] => 16353128
[patent_doc_number] => 10793629
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-10-06
[patent_title] => Compound targeting IL-23A and TNF-alpha and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/052133
[patent_app_country] => US
[patent_app_date] => 2018-08-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 6
[patent_no_of_words] => 26736
[patent_no_of_claims] => 35
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 265
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16052133
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/052133 | Compound targeting IL-23A and TNF-alpha and uses thereof | Jul 31, 2018 | Issued |
Array
(
[id] => 13901903
[patent_doc_number] => 20190040156
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-02-07
[patent_title] => ANTI-TNF- / ANTI-IL-23 IgG BISPECIFIC ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 16/046282
[patent_app_country] => US
[patent_app_date] => 2018-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15759
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 286
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16046282
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/046282 | ANTI-TNF- / ANTI-IL-23 IgG BISPECIFIC ANTIBODIES | Jul 25, 2018 | Abandoned |
Array
(
[id] => 13901885
[patent_doc_number] => 20190040147
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-02-07
[patent_title] => METHODS FOR TREATING CHRONIC SINUSITIS WITH NASAL POLYPS BY ADMINISTERING AN IL-4R ANTAGONIST
[patent_app_type] => utility
[patent_app_number] => 16/038925
[patent_app_country] => US
[patent_app_date] => 2018-07-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38885
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16038925
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/038925 | Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist | Jul 17, 2018 | Issued |
Array
(
[id] => 13823985
[patent_doc_number] => 20190015477
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-17
[patent_title] => MUTEINS OF TEAR LIPOCALIN AND METHODS FOR OBTAINING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/031663
[patent_app_country] => US
[patent_app_date] => 2018-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32502
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16031663
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/031663 | MUTEINS OF TEAR LIPOCALIN AND METHODS FOR OBTAINING THE SAME | Jul 9, 2018 | Abandoned |
Array
(
[id] => 13826587
[patent_doc_number] => 20190016778
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-17
[patent_title] => TARGETED HETERODIMERIC Fc FUSION PROTEINS CONTAINING IL-15 IL-15alpha AND ANTIGEN BINDING DOMAINS
[patent_app_type] => utility
[patent_app_number] => 16/025963
[patent_app_country] => US
[patent_app_date] => 2018-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52650
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16025963
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/025963 | Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains | Jul 1, 2018 | Issued |
Array
(
[id] => 14072367
[patent_doc_number] => 20190085071
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-03-21
[patent_title] => Antagonists to IL-6 to Raise Albumin and/or Lower CRP
[patent_app_type] => utility
[patent_app_number] => 16/015431
[patent_app_country] => US
[patent_app_date] => 2018-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 86378
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16015431
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/015431 | Antagonists to IL-6 to Raise Albumin and/or Lower CRP | Jun 21, 2018 | Abandoned |
Array
(
[id] => 16090459
[patent_doc_number] => 20200199216
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-25
[patent_title] => IL17A Antibodies and Antagonists for Veterinary Use
[patent_app_type] => utility
[patent_app_number] => 16/621012
[patent_app_country] => US
[patent_app_date] => 2018-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27805
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -96
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16621012
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/621012 | IL17A antibodies and antagonists for veterinary use | Jun 17, 2018 | Issued |
Array
(
[id] => 16696726
[patent_doc_number] => 10947307
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-16
[patent_title] => Antibody formulations
[patent_app_type] => utility
[patent_app_number] => 16/002932
[patent_app_country] => US
[patent_app_date] => 2018-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 20
[patent_no_of_words] => 21633
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 177
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16002932
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/002932 | Antibody formulations | Jun 6, 2018 | Issued |
Array
(
[id] => 15913061
[patent_doc_number] => 10653752
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-05-19
[patent_title] => Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
[patent_app_type] => utility
[patent_app_number] => 15/997406
[patent_app_country] => US
[patent_app_date] => 2018-06-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 20521
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15997406
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/997406 | Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure | Jun 3, 2018 | Issued |
Array
(
[id] => 13428049
[patent_doc_number] => 20180265567
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-09-20
[patent_title] => IL-33 Antagonists and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 15/991763
[patent_app_country] => US
[patent_app_date] => 2018-05-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13699
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15991763
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/991763 | IL-33 antagonists and uses thereof | May 28, 2018 | Issued |